CF PharmTech, Inc. (02652) disclosed a Next Day Disclosure Return covering share repurchase activities executed on 30 January 2026. According to the announcement, a total of 14,500 shares were repurchased on the Hong Kong Stock Exchange, with a price range of HKD 35.74 to HKD 36.22 per share and an aggregate consideration of approximately HKD 520,020. These repurchased shares are classified as treasury shares.

The disclosure stated that the opening balance of treasury shares stood at 154,500 on 29 January 2026. Following this latest acquisition, the closing balance of treasury shares increased to 169,000, while the total number of issued shares remained at 302,223,586, with 302,054,586 shares outstanding (excluding treasury shares) as of 30 January 2026.

The report further noted that the share repurchase plan was authorized on 16 December 2025, granting approval for buying back up to 30,222,358 shares. As of the date of the disclosure, 169,000 shares had been repurchased in total under this mandate, representing approximately 0.0559% of the company’s issued shares (excluding treasury shares) as of the authorization date.